Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease

References

• KaliaLVLangAEParkinson’s diseaseLancet2015386999689691225904081
   PubMed Web of Science ®Google Scholar
• ConnollyBSLangAEPharmacological treatment of Parkinson disease: a reviewJAMA2014311161670168324756517
   PubMed Web of Science ®Google Scholar
• GuridiJGonzalez-RedondoRObesoJAClinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson’s diseaseParkinson Dis20122012943159
   PubMed Web of Science ®Google Scholar
• AhlskogJEMuenterMDFrequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literatureMov Disord200116344845811391738
   PubMed Web of Science ®Google Scholar
• HechtnerMCVogtTZollnerYQuality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countriesParkinsonism Relat Disord201420996997424953743
   PubMed Web of Science ®Google Scholar
• Perez-LloretSNegre-PagesLDamierPL-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK surveyEur J Neurol201724121532153828940893
   PubMed Web of Science ®Google Scholar
• KhlebtovskyARigbiAMelamedEPatient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesiasJ Neural Transm (Vienna)2012119111367137122437202
   PubMed Web of Science ®Google Scholar
• PapathanouMRoseSMcCrearyAJennerPInduction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned ratsEur J Neurosci201133122247225421615558
   PubMed Web of Science ®Google Scholar
• IravaniMMJennerPMechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulationJ Neural Transm (Vienna)2011118121661169021881839
   PubMed Web of Science ®Google Scholar
• DeLongMRWichmannTBasal ganglia circuits as targets for neuromodulation in Parkinson diseaseJAMA Neurol201572111354136026409114
   PubMed Web of Science ®Google Scholar
• FinlayCDutySTherapeutic potential of targeting glutamate receptors in Parkinson’s diseaseJ Neural Transm (Vienna)2014121886188024557498
   PubMed Web of Science ®Google Scholar
• BravoSARangel-BarajasCGarduñoBFPathophysiology of L-dopa induced dyskinesia–changes in D1/D3 receptors and their signaling pathwayRanaAQA Synopsis of Parkinson’s DiseaseRijekaInTech2014 Ch. 05
   Google Scholar
• ElahiBPhielippNChenRN-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysisCan J Neurol Sci201239446547222728853
   PubMed Web of Science ®Google Scholar
• VijayakumarDJankovicJDrug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesiaDrugs201676775977727091215
   PubMed Web of Science ®Google Scholar
• AntoniniAFungVSBoydJTEffect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patientsMov Disord201631453053726817533
   PubMed Web of Science ®Google Scholar
• HubsherGHaiderMOkunMSAmantadine: the journey from fighting flu to treating Parkinson diseaseNeurology201278141096109922474298
   PubMed Web of Science ®Google Scholar
• Von VigtlanderPFMooreKEDopamine: release from the brain in vivo by amantadineScience197117440074084105111993
   PubMed Web of Science ®Google Scholar
• HeikkilaRECohenGEvaluation of amantadine as a releasing agent or uptake blocker for H3-dopamine in rat brain slicesEur J Pharmacol19722021561604651205
   PubMed Web of Science ®Google Scholar
• DanyszWParsonsCGKornhuberJSchmidtWJQuackGAminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents–preclinical studiesNeurosci Biobehav Rev19972144554689195603
   PubMed Web of Science ®Google Scholar
• MizoguchiKYokooHYoshidaMTanakaTTanakaMAmantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonismBrain Res19946621–22552587859080
   PubMed Web of Science ®Google Scholar
• BlanchetPJKonitsiotisSChaseTNAmantadine reduces levodopa-induced dyskinesias in parkinsonian monkeysMov Disord19981357988029756148
   PubMed Web of Science ®Google Scholar
• Symmetrel (amantadine hydrochloride) [prescribing information]Chadds Ford, PAEndo Pharmaceuticals Inc2009
   Google Scholar
• BrighamEFJohnstonTHBrownCPharmacokinetic/ pharmacodynamic analysis of amantadine for levodopa-induced dyskinesia: correlation of therapeutic plasma concentrations from multiple species with humans. Program No. 573.052017Neuroscience Meeting PlannerWashington, DCSociety for Neuroscience2017
   Google Scholar
• Gocovrihcp.com Available from: https://www.gocovrihcp.com/dosing-and-pharmacokinetics/Accessed December 29, 2017
   Google Scholar
• Gocovri (amantadine) extended release capsules [package inert]Emeryville, CAAdamas Pharmaceuticals, Inc2017
   Google Scholar
• Verhagen MetmanLDel DottoPvan den MunckhofPFangJMouradianMMChaseTNAmantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s diseaseNeurology1998505132313269595981
   PubMed Web of Science ®Google Scholar
• MetmanLVDel DottoPLePooleKKonitsiotisSFangJChaseTNAmantadine for levodopa-induced dyskinesias: a 1-year follow-up studyArch Neurol199956111383138610555659
   PubMedGoogle Scholar
• SnowBJMacdonaldLMcAuleyDWallisWThe effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled studyClin Neuropharmacol2000232828510803797
   PubMed Web of Science ®Google Scholar
• ThomasAIaconoDLucianoALArmellinoKDi IorioAOnofrjMDuration of amantadine benefit on dyskinesia of severe Parkinson’s diseaseJ Neurol Neurosurg Psychiatry200475114114314707325
   PubMed Web of Science ®Google Scholar
• WolfESeppiKKatzenschlagerRLong-term antidyskinetic efficacy of amantadine in Parkinson’s diseaseMov Disord201025101357136320198649
   PubMed Web of Science ®Google Scholar
• Ory-MagneFCorvolJCAzulayJPWithdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trialNeurology201482430030724371304
   PubMed Web of Science ®Google Scholar
• PahwaRTannerCMHauserRAAmantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study)Mov Disord201530678879525650051
   PubMed Web of Science ®Google Scholar
• PahwaRTannerCMHauserRAADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in parkinson disease (EASE LID Study): a randomized clinical trialJAMA Neurol201774894194928604926
   PubMed Web of Science ®Google Scholar
• OertelWEggertKPahwaRRandomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3)Mov Disord201732121701170928833562
   PubMed Web of Science ®Google Scholar
• GoetzCGNuttJGStebbinsGTThe Unified Dyskinesia Rating Scale: presentation and clinimetric profileMov Disord200823162398240319025759
   PubMed Web of Science ®Google Scholar
• HauserRAPahwaRTannerCMADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety StudyJ Parkinsons Dis20177351152228777755
   PubMedGoogle Scholar
• LeWittPAFahnSLevodopa therapy for Parkinson disease: a look backward and forwardNeurology20168614 Suppl 1S3S1227044648
   PubMed Web of Science ®Google Scholar
• PahwaRFactorSALyonsKEPractice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200666798399516606909
   PubMed Web of Science ®Google Scholar
• FoxSHKatzenschlagerRLimSYThe movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s diseaseMov Disord201126Suppl 3S2S4122021173
   PubMed Web of Science ®Google Scholar
• GoetzCGDamierPHickingCSarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trialMov Disord200722217918617094088
   PubMed Web of Science ®Google Scholar
• LewittPAHauserRALuMRandomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)Neurology201279216316922744665
   PubMed Web of Science ®Google Scholar
• KumarRHauserRAMostilloJMavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson’s disease patientsInt J Neurosci20161261202424007304
   PubMed Web of Science ®Google Scholar
• IsaacsonSPahwaRTannerCADS-5102 provided reduction in motor complications in Parkinson’s disease patients with levodopa-induced dyskinesia switched from amantadine IR: subgroup analysis from open-label study (ease LID 2)J Neurol Sci2017381355
   Web of Science ®Google Scholar